Page 10 - Aurobindo Pharma

Aurobindo Pharma gets USFDA nod for cancer treatment injection

Drug firm Aurobindo Pharma on Friday said its arm Eugia Pharma Specialities has received approval from the US health regulator for Cyclophosphamide injection, used in the treatment of several types of cancer. The company's subsidiary "Eugia Pharma Specialities Ltd has received a 505(b)(2) NDA approval from the US Food & Drug Administration (USFDA) for its Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vial," Aurobindo Pharma said in a regulatory filing. The product will be available in ready-to-use injection preparation, it added. "The product shall be launched in the US market in the near term and will be manufactured in Eugia's manufacturing facility in India," Aurobindo Pharma said. According to IQVIA, the approved product has an addressable market size of USD 170 million for the twelve months ending June 2021, it added. Cyclophosphamide Injection is indicated for malignant lymphomas, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, adenocarcinoma of the ...

Two stock recommendations from Osho Krishan of Anand Rathi

Aurobindo Pharma has corrected over 35 per cent from its lifetime high and has plunged below all its major exponential moving averages

Aurobindo Pharma calls off agreement to pick stake in Cronus; stock up 6%

Aurobindo Pharma, on August 12, 2021, had entered into binding agreements with Cronus Pharma Specialities India Private Limited for acquisition of 51 per cent ownership

Stocks to watch: Nuvoco Vistas, Auro Pharma, Ujjivan SFB, Adani Group cos

Market regulator Sebi kept the proposed Rs 4,500-crore initial share-sale of edible oil major Adani Wilmar in "abeyance"

Aurobindo Pharma's Rs 450-cr deal to acquire 51% in Cronus Pharma cancelled

Aurobindo Pharma Ltd on Friday said its Rs 450-crore deal to acquire 51 per cent stake in Cronus Pharma Specialities India Pvt Ltd (Cronus) has been cancelled

Aurobindo Pharma hits 52-week low, slips 25% in one month

The stock of the pharmaceutical company was trading at its lowest level since June 2020

Near term upsides for Aurobindo Pharma stock capped on weak US outlook

The company has been making small acquisitions to bridge the growth gap

Aurobindo Pharma dips 5% on weak operational performance in June quarter

Aurobindo Pharma has entered into definitive agreements under which the Company will subscribe to fresh equity shares in Cronus amounting to Rs 420 crore

Aurobindo Pharma Q1 consolidated net profit declines 2% to Rs 770 crore

Aurobindo Pharma on Thursday reported a 1.68 per cent decline in its consolidated net profit to Rs 769.97 crore for the quarter ended on June 30, 2021, mainly on account of reduction in expenses

Aurobindo Pharma channelising efforts to commercialise Covid-19 vaccine

The Hyderabad-based drug major is looking to develop products with higher complexity, focus on injectables business and expand business in high growth markets like China.

Injectables consolidation could fetch higher valuations for Aurobindo

Separate listing could capture strong growth rates which is not the case in the current structure

Aurobindo Pharma to transfer biz in Unit-4 to arm Eugia Pharma; stock up 4%

The company said the transfer of the business undertaking will be done for a lumpsum consideration of Rs 876 crore

Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on

MSTC's stock has been in a consolidation phase for quite some time maintaining the base near 255 levels and currently has given a bullish candle pattern in the daily chart

Nifty Pharma index hits new high; Aurobindo, Dr Reddy's gain over 3%

Marksans Pharma and Novartis India from the S&P BSE Healthcare index zoomed 20 per cent each

Lack of near-term triggers to cap upsides in Aurobindo Pharma

Upsides from capex and investments across segments are at least three years away

Stocks to watch: HDFC Bank, M&M, BoB, Affle (India), Aurobindo Pharma, PNB

Bank of Baroda (BoB) reported a standalone net loss of Rs 1,047 crore in the quarter ended March 2021, as it shifted to a new tax regime

Strong injectables portfolio to support Aurobindo Pharma's growth

The stock has been underperforming recent months and trades at a discount to peers

Aurobindo Pharma steady as analysts watch numbers for near-term growth

The company's investments across segments will take at least two years to play out, say analysts

Aurobindo Pharma Q3 net profit zooms over four-fold to Rs 2,946.32 cr

Aurobindo Pharma reported an over four-fold jump in its consolidated net profit to Rs 2,946.32 crore for the quarter ended December 31, 2020 mainly on account of one time exceptional gains.

Aurobindo gains 5% on govt nod for promotion of manufacturing bulk drugs

Aurobindo Pharma (through Lyfius Pharma) has received government approval for setting up plants for production of Penicillin-G and 7-ACA, under the PLI scheme